Caplin Point Laboratories Limited (BOM:524742)
India · Delayed Price · Currency is INR 1,739.65
-7.25 (-0.42%)
At close: Feb 12, 2026
Caplin Point Laboratories Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Operating Revenue | 20,895 | 19,375 | 16,941 | 14,667 | 12,694 | 10,613 |
Other Revenue | 21 | 21 | 20.1 | 15.9 | 15.4 | 10.6 |
| 20,916 | 19,396 | 16,961 | 14,683 | 12,710 | 10,624 | |
Revenue Growth (YoY) | 10.65% | 14.35% | 15.51% | 15.53% | 19.64% | 22.96% |
Cost of Revenue | 8,527 | 8,017 | 7,561 | 6,792 | 5,724 | 4,806 |
Gross Profit | 12,389 | 11,379 | 9,400 | 7,891 | 6,986 | 5,817 |
Selling, General & Admin | 1,868 | 1,779 | 1,437 | 1,371 | 1,154 | 1,026 |
Research & Development | 766.8 | 766.8 | 737.2 | 631.9 | 592.7 | 536.9 |
Other Operating Expenses | 2,448 | 2,305 | 1,683 | 1,456 | 1,275 | 952 |
Operating Expenses | 5,792 | 5,509 | 4,391 | 3,908 | 3,489 | 2,884 |
Operating Income | 6,597 | 5,870 | 5,009 | 3,984 | 3,496 | 2,933 |
Interest Expense | -6.8 | -6.1 | -7.8 | -7.8 | -7 | -15.9 |
Interest & Investment Income | 636.4 | 636.4 | 472.8 | 354.1 | 235 | 186.1 |
Earnings From Equity Investments | 1.2 | -0.1 | 2.7 | 0.8 | - | - |
Currency Exchange Gain (Loss) | 207.8 | 207.8 | 113.1 | 138.2 | 109.8 | 7.2 |
Other Non Operating Income (Expenses) | 262 | 97.2 | 60.7 | 48.2 | 23 | 31.5 |
EBT Excluding Unusual Items | 7,698 | 6,805 | 5,651 | 4,517 | 3,857 | 3,142 |
Gain (Loss) on Sale of Assets | -37.6 | -37.6 | -6.5 | -3.6 | 1.2 | -6 |
Pretax Income | 7,660 | 6,768 | 5,644 | 4,514 | 3,858 | 3,136 |
Income Tax Expense | 1,439 | 1,357 | 1,030 | 743.6 | 773.7 | 621.9 |
Earnings From Continuing Operations | 6,221 | 5,411 | 4,614 | 3,770 | 3,085 | 2,514 |
Minority Interest in Earnings | -84.3 | -47.8 | -43.3 | -7.3 | -86.1 | -91.6 |
Net Income | 6,137 | 5,363 | 4,571 | 3,763 | 2,998 | 2,423 |
Net Income to Common | 6,137 | 5,363 | 4,571 | 3,763 | 2,998 | 2,423 |
Net Income Growth | 19.09% | 17.33% | 21.48% | 25.49% | 23.76% | 12.68% |
Shares Outstanding (Basic) | 76 | 76 | 76 | 76 | 76 | 76 |
Shares Outstanding (Diluted) | 76 | 76 | 76 | 77 | 76 | 76 |
Shares Change (YoY) | -0.22% | 0.05% | -0.26% | 0.18% | 0.07% | 0.11% |
EPS (Basic) | 80.73 | 70.57 | 60.19 | 49.62 | 39.61 | 32.03 |
EPS (Diluted) | 80.50 | 70.25 | 59.90 | 49.18 | 39.26 | 31.71 |
EPS Growth | 19.36% | 17.28% | 21.80% | 25.27% | 23.81% | 12.45% |
Free Cash Flow | - | 2,409 | 1,726 | 779 | 2,456 | 1,953 |
Free Cash Flow Per Share | - | 31.55 | 22.61 | 10.18 | 32.15 | 25.59 |
Dividend Per Share | 3.000 | 6.000 | 5.000 | 4.500 | 4.000 | 3.000 |
Dividend Growth | -45.45% | 20.00% | 11.11% | 12.50% | 33.33% | 20.00% |
Gross Margin | 59.23% | 58.67% | 55.42% | 53.74% | 54.96% | 54.76% |
Operating Margin | 31.54% | 30.26% | 29.53% | 27.13% | 27.51% | 27.61% |
Profit Margin | 29.34% | 27.65% | 26.95% | 25.62% | 23.59% | 22.80% |
Free Cash Flow Margin | - | 12.42% | 10.17% | 5.30% | 19.32% | 18.38% |
EBITDA | 7,303 | 6,487 | 5,507 | 4,399 | 3,939 | 3,285 |
EBITDA Margin | 34.92% | 33.44% | 32.46% | 29.96% | 30.99% | 30.92% |
D&A For EBITDA | 705.8 | 616.4 | 497.2 | 415.8 | 442.3 | 351.5 |
EBIT | 6,597 | 5,870 | 5,009 | 3,984 | 3,496 | 2,933 |
EBIT Margin | 31.54% | 30.26% | 29.53% | 27.13% | 27.51% | 27.61% |
Effective Tax Rate | 18.78% | 20.05% | 18.25% | 16.48% | 20.05% | 19.83% |
Revenue as Reported | 22,024 | 20,339 | 17,610 | 15,227 | 13,082 | 10,848 |
Updated Dec 31, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.